Keystone Nano, a producer of nanoscale solutions for the treatment of cancer, has announced the publication of a manuscript describing the preclinical development of the company’s lead product.
The drug, Ceramide Nanoliposome, is designed to treat cancer by providing selectively killing cancer cells without harming normal cells.
Keystone Nano is currently compiling an Investigational New Drug (IND) filing on Ceramide Nanoliposome for review by the US Food and Drug Administration. After being classified as an IND, the drug can enter the first phase of clinical trials.
The company anticipates that the initial clinical trial will treat patients with a range of cancers. After this initial testing is complete, the company anticipates enrolling in clinical testing patients with Liver Cancer or other difficult to treat cancers.
The paper was published in June 2015 issue of Biological Chemistry and authored by Dr. Mylisa Parette, Keystone Nano’s Research Manager, Dr. Mark Kester, Keystone Nano’s Chief Medical Officer, Ms. Jocelyn Bassler, Keystone Nano Research Chemist, Dr. Carly Carter, Keystone Research Team Leader and Mr. Jeff Davidson, Keystone Nano’s CEO. Also contributing was Dr. Todd Fox of the University of Virginia.